

Melanoma Oncotrail RGCC™

Results



Analysis on a patient test patient 1 suffering from Melanoma carcinoma stage II.



The sample that was sent to us for analysis was a sample of 20ml Blood that contains anti-coagulant, and packed with an ice pack.

Laboratory Process

Isolation of malignant cells using flow cytometry with which the circulating tumor cells are enumerated and immunophenotyped

The results during the isolation procedure are presented below

Table of markers

Significant CD45 positive cells (Hematologic origin cells)

Nanog

Positive

OKT-4

Negative

Sox-2

Dim

CD15

Positive

CD45 negative cells (non Hematologic origin)

Nanog

Positive (25% of all CTC)

OKT-4

Negative

Sox-2

Dim

CD63

Positive (50% of all CTC)

EpCam

Negative

EpCAm+ve: 2.7 cells/ml

CD133

Dim

c-MET

Positive (75% of all CTC)

CD31

Negative

PanCK

Dim

Index of markers

CD133, Sox-2*, OKT-4*, Nanog*

Tumor stem cell marker

c-MET*

Membrane antigen that regulates the mesenchymal to epithelial transition

CD34*

Hematological stem cell and blast cell marker, Epithelioid

CD45

Hematologic origin cell

BCR-ABL, CD30

Hematologic malignancy marker

CD44

Tumor stem cell marker

CD15

Hematological malignancy marker

CD19

(CD45 negative cells – Non Hematologic origin cells) lung neuroendocrine malignancy

(CD45 positive cells – Hematologic origin cells) Hematological malignancy

CD31

Endothelial cell membrane antigen

CD63

Melanoma cell marker

CD99

Sarcoma marker

EpCam

Epithelial origin marker

MUC-1

Breast cancer antigen

PSMA

Prostate specific cancer stem cell membrane antigen

VHL mut

Renal carcinoma marker

panCK

Epithelial origin cell marker

* Significant markers

Ioannis Papatiriu M.D., PhD Head of molecular medicine dpt of R.G.C.C -Research Genetic Cancer Centre International GmbH Baarerstr 95, 6300, Zug, Switzerland

Tel: +41-41-7250560 Website: www.rgcc-group.com E-mail: medical@rgcc-genlab.com



The final results after the isolation procedure are presented below:

We notice that after isolation procedure there are remaining malignant cells.

The concentration of these cells was isolated 3.3 cells/ml, SD +/- 0.3cells.

Index of circulating cells number

If over limit: Advanced or progression of disease. If less than limit: Early disease or disease is responding to a treatment plan.

Breast Cancer

< 5 cells / 7.5 ml

Prostate Cancer

< 20 cells / ml

Sarcoma

< 15 cells / 6.5 ml

Colon Cancer

< 5 cells / ml

Lung Cancer

(Lc=0, r=0.99):< 10 cells / ml

All cancer types other than those listed above should be < 5 cells / ml

Disclaimers

*This test will NOT DETECT cancers of the brain or other cancers that have been "encapsulated" by the body, not releasing circulating tumor or stem cells (CTC, CSC) into the blood stream or if any of these cells are dormant. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist.No test is 100% accurate.




*The methodology has a sensitivity of 86,2% and specificity of 83,9%

Sincerely,



Ioannis Papasotiriou MD., PhD Head of molecular medicine dpt. of R.G.C.C.-Research Genetic Cancer Centre International GmbH

Patient Name: test patient 1 - Date: 23 Feb 2022



Overlay #	Filename	Gate	# of Events	X Geometric Mean	Y Geometric Mean	% of gated cells	% of all cells
1	De Oliveira Gomes psma-cd45-ck 00100787 677.LMD	None	50000	6.79	1.58	100.00	100.00
1	De Oliveira Gomes psma-cd45-ck 00100787 677.LMD	Gate 1	3030	2.58	1.43	6.06	6.06
1	De Oliveira Gomes psma-cd45-ck 00100787 677.LMD	Gate 2	3	6.38	13.34	0.01	0.01
1	De Oliveira Gomes psma-cd45-ck 00100787 677.LMD	Gate 3	4	2.23	4.07	0.01	0.01